<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35182920</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3557</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>272</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy</Title>
          <ISOAbbreviation>Spectrochim Acta A Mol Biomol Spectrosc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Different approaches for the assessment of greenness of spectrophotometric methodologies utilized for resolving the spectral overlap of newly approved binary hypoglycemic pharmaceutical mixture.</ArticleTitle>
        <Pagination>
          <StartPage>120998</StartPage>
          <MedlinePgn>120998</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.saa.2022.120998</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1386-1425(22)00146-9</ELocationID>
        <Abstract>
          <AbstractText>Simultaneous measurement of saxagliptin hydrochloride (SAG) and dapagliflozin propanediol monohydrate (DAG) in bulk powder, laboratory-prepared mixtures, and pharmaceutical dosage form were applied by utilizing three precise and sensitive spectrophotometric techniques which were developed and validated. The first method was the induced dual-wavelength approach (IDW), which relied primarily on the use of alternative equality factors (F) to abolish the effect of DAG when determining SAG and vice versa. The ratio difference method (RDM) was the second method, which used 25 μg/ml of DAG and 20 μg/ml of SAG as divisors to determine the amplitude difference on the ratio spectrum of SAG and DAG, respectively. SAG was determined at λ<sub>max</sub> 221 nm after plateau subtraction followed by multiplication by the divisor of DAG 25 μg/ml using the third method, ratio subtraction coupled with extended ratio subtraction method (RSER). Subsequently, using an extension ratio subtraction of the spectra, DAG was determined at λ<sub>max</sub> 225 nm was determined. The developed methods were effectively used to estimate SAG and DAG in laboratory-prepared mixtures and pharmaceutical dosage forms, with satisfactory recoveries. The methodologies were assessed for their environmental friendliness using the analytical eco-scale, analytical GREEnness calculator, and green analytical procedureindex (GAPI). These methodologies were validated following the International Conference on Harmonisation (ICH) requirements. A statistical comparison of the obtained findings to those of the published method revealed no significant differences in precision and accuracy. Because of their high precision and cost-effectiveness, the developed methods can be used in quality control laboratories to determine the binary mixture.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fawzy</LastName>
            <ForeName>Michael Gamal</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hassan</LastName>
            <ForeName>Wafaa Elsayed</ForeName>
            <Initials>WE</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mostafa</LastName>
            <ForeName>Alaa Ahmed</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt. Electronic address: Alaaazzam30@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sayed</LastName>
            <ForeName>Rania Adel</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Spectrochim Acta A Mol Biomol Spectrosc</MedlineTA>
        <NlmUniqueID>9602533</NlmUniqueID>
        <ISSNLinking>1386-1425</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013053" MajorTopicYN="N">Spectrophotometry</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dapagliflozin</Keyword>
        <Keyword MajorTopicYN="N">Eco-friendly</Keyword>
        <Keyword MajorTopicYN="N">Extended ratio subtraction</Keyword>
        <Keyword MajorTopicYN="N">Induced wavelength</Keyword>
        <Keyword MajorTopicYN="N">Ratio difference</Keyword>
        <Keyword MajorTopicYN="N">Saxagliptin</Keyword>
        <Keyword MajorTopicYN="N">UV spectrophotometry</Keyword>
        <Keyword MajorTopicYN="N">Validation</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35182920</ArticleId>
        <ArticleId IdType="doi">10.1016/j.saa.2022.120998</ArticleId>
        <ArticleId IdType="pii">S1386-1425(22)00146-9</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
